Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

The Current Role of Microfluidics in Radiofluorination Chemistry.

Knapp KA, Nickels ML, Manning HC.

Mol Imaging Biol. 2019 Sep 4. doi: 10.1007/s11307-019-01414-6. [Epub ahead of print]

PMID:
31485889
2.

Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer.

Uddin MJ, Wilson AJ, Crews BC, Malerba P, Uddin MI, Kingsley PJ, Ghebreselasie K, Daniel CK, Nickels ML, Tantawy MN, Jashim E, Manning HC, Khabele D, Marnett LJ.

ACS Omega. 2019 May 31;4(5):9251-9261. doi: 10.1021/acsomega.9b01093. Epub 2019 May 24.

3.

Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.

Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA.

Clin Cancer Res. 2019 Feb 15;25(4):1435. doi: 10.1158/1078-0432.CCR-18-4266. No abstract available.

PMID:
30770494
4.

Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.

Joseph JD, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, Walter K, Blake RA, Nonomiya J, Guan Z, Kategaya L, Govek SP, Lai AG, Kahraman M, Brigham D, Sensintaffar J, Lu N, Shao G, Qian J, Grillot K, Moon M, Prudente R, Bischoff E, Lee KJ, Bonnefous C, Douglas KL, Julien JD, Nagasawa JY, Aparicio A, Kaufman J, Haley B, Giltnane JM, Wertz IE, Lackner MR, Nannini MA, Sampath D, Schwarz L, Manning HC, Tantawy MN, Arteaga CL, Heyman RA, Rix PJ, Friedman L, Smith ND, Metcalfe C, Hager JH.

Elife. 2019 Jan 7;8. pii: e44851. doi: 10.7554/eLife.44851.

5.

Ventral striatal dopamine transporter availability is associated with lower trait motor impulsivity in healthy adults.

Smith CT, San Juan MD, Dang LC, Katz DT, Perkins SF, Burgess LL, Cowan RL, Manning HC, Nickels ML, Claassen DO, Samanez-Larkin GR, Zald DH.

Transl Psychiatry. 2018 Dec 7;8(1):269. doi: 10.1038/s41398-018-0328-y.

6.

Automated radiosynthesis of 5-[11C]l-glutamine, an important tracer for glutamine utilization.

Rosenberg AJ, Nickels ML, Schulte ML, Manning HC.

Nucl Med Biol. 2018 Dec;67:10-14. doi: 10.1016/j.nucmedbio.2018.09.002. Epub 2018 Oct 15.

PMID:
30359787
7.

Mutant KRAS Exosomes Alter the Metabolic State of Recipient Colonic Epithelial Cells.

Zhang Q, Jeppesen DK, Higginbotham JN, Demory Beckler M, Poulin EJ, Walsh AJ, Skala MC, McKinley ET, Manning HC, Hight MR, Schulte ML, Watt KR, Ayers GD, Wolf MM, Andrejeva G, Rathmell JC, Franklin JL, Coffey RJ.

Cell Mol Gastroenterol Hepatol. 2018 Jan 31;5(4):627-629.e6. doi: 10.1016/j.jcmgh.2018.01.013. eCollection 2018. No abstract available.

8.

Preclinical Evaluation of a Novel TSPO PET Ligand 2-(7-Butyl-2-(4-(2-[18F]Fluoroethoxy)phenyl)-5-Methylpyrazolo[1,5-a]Pyrimidin-3-yl)-N,N-Diethylacetamide (18F-VUIIS1018A) to Image Glioma.

Tang D, Li J, Nickels ML, Huang G, Cohen AS, Manning HC.

Mol Imaging Biol. 2019 Feb;21(1):113-121. doi: 10.1007/s11307-018-1198-7.

PMID:
29869061
9.

Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017.

Okunieff P, Casey-Sawicki K, Lockney NA, Hoppe BS, Enderling H, Pinnix C, Welsh J, Krishnan S, Yothers G, Brown M, Knox S, Bristow R, Spellman P, Mitin T, Nabavizadeh N, Jaboin J, Manning HC, Feng F, Galbraith S, Solanki AA, Harkenrider MM, Tuli R, Decker RH, Finkelstein SE, Hsu CC, Ha CS, Jagsi R, Shumway D, Daly M, Wang TJC, Fitzgerald TJ, Laurie F, Marshall DT, Raben D, Constine L, Thomas CR Jr, Kachnic LA.

Clin Cancer Res. 2018 Aug 1;24(15):3500-3509. doi: 10.1158/1078-0432.CCR-17-3202. Epub 2018 Apr 16.

10.

A simple microfluidic platform for rapid and efficient production of the radiotracer [18F]fallypride.

Zhang X, Liu F, Knapp KA, Nickels ML, Manning HC, Bellan LM.

Lab Chip. 2018 May 1;18(9):1369-1377. doi: 10.1039/c8lc00167g.

PMID:
29658049
11.

Evaluation of the novel TSPO radiotracer 2-(7-butyl-2-(4-(2-([18F]fluoroethoxy)phenyl)-5-methylpyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide in a preclinical model of neuroinflammation.

Tang D, Fujinaga M, Hatori A, Zhang Y, Yamasaki T, Xie L, Mori W, Kumata K, Liu J, Manning HC, Huang G, Zhang MR.

Eur J Med Chem. 2018 Apr 25;150:1-8. doi: 10.1016/j.ejmech.2018.02.076. Epub 2018 Feb 24.

PMID:
29505933
12.

DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer.

Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, Zahnow CA, Nickels ML, Liu F, Tantawy MN, Sanders ME, Manning HC, Balko JM.

Nat Commun. 2018 Jan 16;9(1):248. doi: 10.1038/s41467-017-02630-w.

13.

Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models.

Schulte ML, Fu A, Zhao P, Li J, Geng L, Smith ST, Kondo J, Coffey RJ, Johnson MO, Rathmell JC, Sharick JT, Skala MC, Smith JA, Berlin J, Washington MK, Nickels ML, Manning HC.

Nat Med. 2018 Feb;24(2):194-202. doi: 10.1038/nm.4464. Epub 2018 Jan 15.

14.

Intracardiac Metastases Detected by 18F-FSPG PET/CT.

Magarik MA, Walker RC, Gilbert J, Manning HC, Massion PP.

Clin Nucl Med. 2018 Jan;43(1):28-30. doi: 10.1097/RLU.0000000000001883.

15.

Optimized Translocator Protein Ligand for Optical Molecular Imaging and Screening.

Li J, Smith JA, Dawson ES, Fu A, Nickels ML, Schulte ML, Manning HC.

Bioconjug Chem. 2017 Apr 19;28(4):1016-1023. doi: 10.1021/acs.bioconjchem.6b00711. Epub 2017 Feb 13.

PMID:
28156095
16.

18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.

Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA.

Clin Cancer Res. 2017 Jun 15;23(12):3053-3060. doi: 10.1158/1078-0432.CCR-16-2197. Epub 2016 Dec 23. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1435.

17.

A comparative assessment of preclinical chemotherapeutic response of tumors using quantitative non-Gaussian diffusion MRI.

Xu J, Li K, Smith RA, Waterton JC, Zhao P, Ding Z, Does MD, Manning HC, Gore JC.

Magn Reson Imaging. 2017 Apr;37:195-202. doi: 10.1016/j.mri.2016.12.002. Epub 2016 Dec 3.

18.

Evaluation of TSPO PET Ligands [18F]VUIIS1009A and [18F]VUIIS1009B: Tracers for Cancer Imaging.

Tang D, Li J, Buck JR, Tantawy MN, Xia Y, Harp JM, Nickels ML, Meiler J, Manning HC.

Mol Imaging Biol. 2017 Aug;19(4):578-588. doi: 10.1007/s11307-016-1027-9.

19.

Utility of [18F]FSPG PET to Image Hepatocellular Carcinoma: First Clinical Evaluation in a US Population.

Kavanaugh G, Williams J, Morris AS, Nickels ML, Walker R, Koglin N, Stephens AW, Washington MK, Geevarghese SK, Liu Q, Ayers D, Shyr Y, Manning HC.

Mol Imaging Biol. 2016 Dec;18(6):924-934.

20.

Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAFV600E In Vivo.

Schulte ML, Hight MR, Ayers GD, Liu Q, Shyr Y, Washington MK, Manning HC.

Mol Imaging Biol. 2017 Jun;19(3):421-428. doi: 10.1007/s11307-016-1008-z.

21.

18F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma.

Osgood CL, Tantawy MN, Maloney N, Madaj ZB, Peck A, Boguslawski E, Jess J, Buck J, Winn ME, Manning HC, Grohar PJ.

Sci Rep. 2016 Sep 27;6:33926. doi: 10.1038/srep33926.

22.

Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.

Qiao J, Grabowska MM, Forestier-Roman IS, Mirosevich J, Case TC, Chung DH, Cates JM, Matusik RJ, Manning HC, Jin R.

Oncotarget. 2016 Sep 20;7(38):61955-61969. doi: 10.18632/oncotarget.11326.

23.

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.

Joseph JD, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, Walter K, Blake RA, Nonomiya J, Guan Z, Kategaya L, Govek SP, Lai AG, Kahraman M, Brigham D, Sensintaffar J, Lu N, Shao G, Qian J, Grillot K, Moon M, Prudente R, Bischoff E, Lee KJ, Bonnefous C, Douglas KL, Julien JD, Nagasawa JY, Aparicio A, Kaufman J, Haley B, Giltnane JM, Wertz IE, Lackner MR, Nannini MA, Sampath D, Schwarz L, Manning HC, Tantawy MN, Arteaga CL, Heyman RA, Rix PJ, Friedman L, Smith ND, Metcalfe C, Hager JH.

Elife. 2016 Jul 13;5. pii: e15828. doi: 10.7554/eLife.15828. Erratum in: Elife. 2019 Jan 07;8:.

24.

New structure-activity relationships of N-acetamide substituted pyrazolopyrimidines as pharmacological ligands of TSPO.

Li J, Schulte ML, Nickels ML, Manning HC.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3472-7. doi: 10.1016/j.bmcl.2016.06.041. Epub 2016 Jun 16.

25.

Identification and characterization of EGF receptor in individual exosomes by fluorescence-activated vesicle sorting.

Higginbotham JN, Zhang Q, Jeppesen DK, Scott AM, Manning HC, Ochieng J, Franklin JL, Coffey RJ.

J Extracell Vesicles. 2016 Jun 24;5:29254. doi: 10.3402/jev.v5.29254. eCollection 2016.

26.

Mouse Models of Breast Cancer: Platforms for Discovering Precision Imaging Diagnostics and Future Cancer Medicine.

Manning HC, Buck JR, Cook RS.

J Nucl Med. 2016 Feb;57 Suppl 1:60S-8S. doi: 10.2967/jnumed.115.157917. Review.

27.

2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport.

Schulte ML, Khodadadi AB, Cuthbertson ML, Smith JA, Manning HC.

Bioorg Med Chem Lett. 2016 Feb 1;26(3):1044-1047. doi: 10.1016/j.bmcl.2015.12.031. Epub 2015 Dec 11.

28.

Preclinical TSPO Ligand PET to Visualize Human Glioma Xenotransplants: A Preliminary Study.

Buck JR, McKinley ET, Fu A, Abel TW, Thompson RC, Chambless L, Watchmaker JM, Harty JP, Cooper MK, Manning HC.

PLoS One. 2015 Oct 30;10(10):e0141659. doi: 10.1371/journal.pone.0141659. eCollection 2015.

29.

Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer.

Hassanein M, Hight MR, Buck JR, Tantawy MN, Nickels ML, Hoeksema MD, Harris BK, Boyd K, Massion PP, Manning HC.

Mol Imaging Biol. 2016 Feb;18(1):18-23. doi: 10.1007/s11307-015-0862-4.

30.

[(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study.

McKinley ET, Watchmaker JM, Chakravarthy AB, Meyerhardt JA, Engelman JA, Walker RC, Washington MK, Coffey RJ, Manning HC.

Ann Nucl Med. 2015 Jul;29(6):535-42. doi: 10.1007/s12149-015-0974-6. Epub 2015 Apr 22.

31.

World Molecular Imaging Congress 2015: precision medicine visualized.

Manning HC.

Mol Imaging Biol. 2015 Jun;17(3):295-6. doi: 10.1007/s11307-015-0855-3. No abstract available.

PMID:
25862478
32.

High-yielding, automated production of 3'-deoxy-3'-[(18)F]fluorothymidine using a modified Bioscan Coincidence FDG reaction module.

Cheung YY, Nickels ML, McKinley ET, Buck JR, Manning HC.

Appl Radiat Isot. 2015 Mar;97:47-51. doi: 10.1016/j.apradiso.2014.11.011. Epub 2014 Dec 15.

33.

Acetate dependence of tumors.

Comerford SA, Huang Z, Du X, Wang Y, Cai L, Witkiewicz AK, Walters H, Tantawy MN, Fu A, Manning HC, Horton JD, Hammer RE, McKnight SL, Tu BP.

Cell. 2014 Dec 18;159(7):1591-602. doi: 10.1016/j.cell.2014.11.020.

34.

2-Substituted Nγ-glutamylanilides as novel probes of ASCT2 with improved potency.

Schulte ML, Dawson ES, Saleh SA, Cuthbertson ML, Manning HC.

Bioorg Med Chem Lett. 2015 Jan 1;25(1):113-6. doi: 10.1016/j.bmcl.2014.10.098. Epub 2014 Nov 11.

35.

Molecular imaging of folate receptor β-positive macrophages during acute lung inflammation.

Han W, Zaynagetdinov R, Yull FE, Polosukhin VV, Gleaves LA, Tanjore H, Young LR, Peterson TE, Manning HC, Prince LS, Blackwell TS.

Am J Respir Cell Mol Biol. 2015 Jul;53(1):50-9. doi: 10.1165/rcmb.2014-0289OC.

36.

3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer.

McKinley ET, Zhao P, Coffey RJ, Washington MK, Manning HC.

PLoS One. 2014 Sep 23;9(9):e108193. doi: 10.1371/journal.pone.0108193. eCollection 2014.

37.
38.

Utility of [18 F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts.

Whisenant JG, McIntyre JO, Peterson TE, Kang H, Sánchez V, Manning HC, Arteaga CL, Yankeelov TE.

Mol Imaging Biol. 2015 Feb;17(1):119-28. doi: 10.1007/s11307-014-0770-z.

39.
40.

Inducible loss of one Apc allele in Lrig1-expressing progenitor cells results in multiple distal colonic tumors with features of familial adenomatous polyposis.

Powell AE, Vlacich G, Zhao ZY, McKinley ET, Washington MK, Manning HC, Coffey RJ.

Am J Physiol Gastrointest Liver Physiol. 2014 Jul 1;307(1):G16-23. doi: 10.1152/ajpgi.00358.2013. Epub 2014 May 15.

41.

PET radiotracer [¹⁸F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation.

Perrone MG, Malerba P, Uddin J, Vitale P, Panella A, Crews BC, Daniel CK, Ghebreselasie K, Nickels M, Tantawy MN, Manning HC, Marnett LJ, Scilimati A.

Eur J Med Chem. 2014 Jun 10;80:562-568. doi: 10.1016/j.ejmech.2014.04.074. Epub 2014 Apr 29.

42.

A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells.

Hight MR, Cheung YY, Nickels ML, Dawson ES, Zhao P, Saleh S, Buck JR, Tang D, Washington MK, Coffey RJ, Manning HC.

Clin Cancer Res. 2014 Apr 15;20(8):2126-35. doi: 10.1158/1078-0432.CCR-13-2444. Epub 2014 Feb 26.

43.

Microwave-assisted, one-pot reaction of 7-azaindoles and aldehydes: a facile route to novel di-7-azaindolylmethanes.

Uddin MI, Buck JR, Schulte ML, Tang D, Saleh SA, Cheung YY, Harp J, Manning HC.

Tetrahedron Lett. 2014 Jan 1;55(1). doi: 10.1016/j.tetlet.2013.10.143.

44.

Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer.

McKinley ET, Liu H, McDonald WH, Luo W, Zhao P, Coffey RJ, Hanks SK, Manning HC.

PLoS One. 2013 Nov 8;8(11):e80207. doi: 10.1371/journal.pone.0080207. eCollection 2013.

45.

Translocator protein 18 kDa (TSPO) is regulated in white and brown adipose tissue by obesity.

Thompson MM, Manning HC, Ellacott KL.

PLoS One. 2013 Nov 18;8(11):e79980. doi: 10.1371/journal.pone.0079980. eCollection 2013.

46.

Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer.

Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, Skala MC.

Cancer Res. 2013 Oct 15;73(20):6164-74. doi: 10.1158/0008-5472.CAN-13-0527.

47.

Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia.

Katsha A, Soutto M, Sehdev V, Peng D, Washington MK, Piazuelo MB, Tantawy MN, Manning HC, Lu P, Shyr Y, Ecsedy J, Belkhiri A, El-Rifai W.

Gastroenterology. 2013 Dec;145(6):1312-22.e1-8. doi: 10.1053/j.gastro.2013.08.050. Epub 2013 Aug 29.

48.

A novel reporter system for molecular imaging and high-throughput screening of anticancer drugs.

Xie J, Wang C, Virostko J, Manning HC, Pham W, Bauer J, Gore JC.

Chembiochem. 2013 Aug 19;14(12):1494-503. doi: 10.1002/cbic.201300142. Epub 2013 Jul 24.

49.

Knockdown of aberrantly upregulated aryl hydrocarbon receptor reduces tumor growth and metastasis of MDA-MB-231 human breast cancer cell line.

Goode GD, Ballard BR, Manning HC, Freeman ML, Kang Y, Eltom SE.

Int J Cancer. 2013 Dec 15;133(12):2769-80. doi: 10.1002/ijc.28297. Epub 2013 Jul 5.

50.

Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.

McKinley ET, Ayers GD, Smith RA, Saleh SA, Zhao P, Washington MK, Coffey RJ, Manning HC.

PLoS One. 2013;8(3):e58938. doi: 10.1371/journal.pone.0058938. Epub 2013 Mar 15.

Supplemental Content

Loading ...
Support Center